High-Stakes Philanthropy: How a Ford Raptor Giveaway Fuels a Blindness Cure

GILBERT, AZ – June 11, 2026 – On the surface, it’s a fundraiser with the high-octane appeal of a Super Bowl commercial: a custom-built Ford F-150 Raptor, a Ford Explorer ST, and over a quarter-million dollars in prizes. But behind the gleam of polished chrome and the allure of winning big lies a mission of profound urgency. A Race Against Blindness, an Arizona-based nonprofit, has launched its “250 Years, 250 Winners” campaign, an audacious seven-week initiative that leverages America's 250th anniversary to fund the next frontier of genetic medicine. The goal is not to sell raffle tickets, but to buy time—and ultimately, a cure—for children facing a future of progressive blindness.

Founded by Steve and Kristina Johnston after their son Luke was diagnosed with a rare genetic disorder, the organization has pioneered a fundraising model that trades black-tie galas for the broad appeal of high-value giveaways. This strategy is proving remarkably effective, transforming public excitement into millions of dollars for clinical research. The campaign exposes a powerful intersection of technology, marketing, and personal desperation, revealing how innovative funding mechanisms are becoming critical accelerators for life-changing medical breakthroughs.

A New Engine for Philanthropy

In a crowded nonprofit landscape, A Race Against Blindness has cut through the noise by engineering a system that feels less like a donation and more like an opportunity. The “America 250” campaign, with its 250 winners and partnerships with companies like San Tan Ford, Westcott Designs, and KC HiLiTES, is the culmination of a strategy honed since the organization’s founding in 2023. By offering tangible, high-desire prizes, the nonprofit has tapped into a vast audience that extends far beyond those directly affected by inherited retinal diseases.

This model has yielded staggering results. In just over three years, A Race Against Blindness has granted more than $6.1 million directly to clinical trial research. This rapid financial impact is powered by a massive digital community of over 500,000 followers across social media platforms. The organization’s success demonstrates a paradigm shift in charitable giving, where sophisticated digital marketing and community engagement can outperform traditional fundraising methods. The proof is in their public validation: a top-tier Platinum Seal of Transparency from Candid, the nonprofit accountability watchdog, and a near-perfect 4.9-star rating from over 4,300 reviews on Trustpilot.

This approach redefines the concept of a donor. Instead of passive contributors, supporters become active participants in a shared mission, drawn in by the excitement of the sweepstakes but retained by the gravity of the cause. “This campaign is about more than vehicles and prizes,” said Steve Johnston, co-founder of A Race Against Blindness. “America’s 250th is a celebration of hope, resilience, and possibility. We wanted to create something bold and exciting that also helps fund research capable of changing the lives of children facing blindness.”

The Personal Race Against a Rare Disease

The relentless drive behind this innovative fundraising engine is deeply personal. The organization was born from the Johnstons' journey after their son Luke was diagnosed with Bardet-Biedl Syndrome (BBS). BBS is a rare and complex genetic disorder that stems from malfunctioning cilia, the microscopic antenna-like structures on cells. While it affects multiple body systems, its most devastating symptom is progressive vision loss.

Children with BBS often experience night blindness in their early years, which progresses to a loss of peripheral vision, creating a debilitating “tunnel vision” effect. For many, this leads to legal blindness by adolescence or early adulthood. With an incidence as low as 1 in 160,000 people, BBS falls into the category of rare diseases that often struggle to attract significant research funding from large pharmaceutical companies or federal grants, leaving families to navigate a landscape of uncertainty.

“We’ve seen firsthand how communities and businesses can come together around a meaningful mission,” said Kristina Johnston, co-founder. “The America 250 campaign is designed to celebrate our country while bringing real hope to families awaiting treatments and clinical trial opportunities.” For the Johnstons and thousands of families like them, the race is not an abstraction; it is a daily reality. The funds raised are a direct lifeline to researchers working on therapies that could halt or even reverse the genetic clock ticking away their children's sight.

Fueling the Frontier of Gene Therapy

The money raised by A Race Against Blindness is not just filling a gap; it is strategically fueling one of the most promising fields in modern medicine: gene therapy. The organization's focus is on inherited retinal diseases (IRDs), a group of over 250 conditions, including BBS and Retinitis Pigmentosa (RP), caused by mutations in single genes. This makes them prime candidates for gene-based treatments.

The concept is elegant in its directness: deliver a correct copy of a faulty gene to the retinal cells, allowing them to function properly and produce the proteins necessary for vision. The FDA’s 2017 approval of Luxturna, a gene therapy for a specific IRD, proved this was not science fiction. However, that treatment only addresses one of many genetic mutations, and the path from lab to clinic is extraordinarily expensive.

This is where the impact of the nonprofit’s funding becomes tangible. The organization has already committed $3 million from previous fundraisers to Axovia Therapeutics to support an upcoming clinical trial for AXV-101, a gene therapy targeting the BBS1 gene—the most common cause of Bardet-Biedl Syndrome. This funding is critical for moving the therapy, scheduled to begin trials in the UK in mid-2025, into human testing. By de-risking the early stages of development, A Race Against Blindness provides the catalytic capital that larger investors and pharmaceutical partners often require before stepping in.

While larger organizations like the Foundation Fighting Blindness have been funding IRD research for decades, the focused, agile, and highly effective model used by A Race Against Blindness demonstrates the vital role that patient-led advocacy groups can play. They are not just waiting for breakthroughs; they are actively manufacturing the financial environment required for those breakthroughs to happen.